1 Department of Virology, HIV and Hepatitis Research Unit, University of Limpopo, Medunsa Campus/National Health Laboratory Service, Pretoria, South Africa
Article information
Hepatitis Monthly: November 30, 2014,
14 (11); e23660
To Cite:
Gededzha
M P, Mphahlele
M J, Selabe
S G. Characterization of HCV Genotype 5a Envelope Proteins: Implications for Vaccine Development and Therapeutic Entry Target,
Hepat Mon.
2014
;14(11):e23660.
doi: 10.5812/hepatmon.23660.
1. Guidelines for the screening care and treatment of persons with hepatitis C infection. 2014;
2.
Lemon SM, Walker C, Alter MJ, Yi M. Fields Virology. 2007; : 1253-304
3.
Chevaliez S, Pawlotsky JM. Hepatitis C Viruses: Genomes and Molecular Biology. 2006; : 45-7
4.
Drummer HE, Maerz A, Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 2003; 546(2-3): 385-90[PubMed]
5.
Goffard A, Dubuisson J. Glycosylation of hepatitis C virus envelope proteins. Biochimie. 2003; 85(3-4): 295-301[PubMed]
6.
Higginbottom A,
Quinn ER,
Kuo CC,
Flint M,
Wilson LH,
Bianchi E,
et al.
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol. 2000; 74(8): 3642-9[PubMed]
7.
Scarselli E,
Ansuini H,
Cerino R,
Roccasecca RM,
Acali S,
Filocamo G,
et al.
The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 2002; 21(19): 5017-25[PubMed]
8.
Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S. Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies. J Transl Med. 2011; 9: 194[DOI][PubMed]
9.
Brown RJ,
Tarr AW,
McClure CP,
Juttla VS,
Tagiuri N,
Irving WL,
et al.
Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J Gen Virol. 2007; 88: 458-69[DOI][PubMed]
10.
Slater-Handshy T, Droll DA, Fan X, Di Bisceglie AM, Chambers TJ. HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology. 2004; 319(1): 36-48[DOI][PubMed]
11.
Pileri P,
Uematsu Y,
Campagnoli S,
Galli G,
Falugi F,
Petracca R,
et al.
Binding of hepatitis C virus to CD81. Science. 1998; 282(5390): 938-41[PubMed]
12.
Helle F, Dubuisson J. Hepatitis C virus entry into host cells. Cell Mol Life Sci. 2008; 65(1): 100-12[DOI][PubMed]
13.
Schonning K, Jansson B, Olofsson S, Hansen JE. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. J Gen Virol. 1996; 77 ( Pt 4): 753-8[PubMed]
14.
Wei X,
Decker JM,
Wang S,
Hui H,
Kappes JC,
Wu X,
et al.
Antibody neutralization and escape by HIV-1. Nature. 2003; 422(6929): 307-12[DOI][PubMed]
15.
Bugli F,
Mancini N,
Kang CY,
Di Campli C,
Grieco A,
Manzin A,
et al.
Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol. 2001; 75(20): 9986-90[DOI][PubMed]
16.
Giang E,
Dorner M,
Prentoe JC,
Dreux M,
Evans MJ,
Bukh J,
et al.
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci U S A. 2012; 109(16): 6205-10[DOI][PubMed]
17.
Fournillier A,
Wychowski C,
Boucreux D,
Baumert TF,
Meunier JC,
Jacobs D,
et al.
Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol. 2001; 75(24): 12088-97[DOI][PubMed]
18.
El-Awady MK,
Tabll AA,
Atef K,
Yousef SS,
Omran MH,
El-Abd Y,
et al.
Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro. World J Gastroenterol. 2006; 12(16): 2530-5[PubMed]
19.
El-Awady MK,
Tabll AA,
El-Abd YS,
Yousif H,
Hegab M,
Reda M,
et al.
Conserved peptides within the E2 region of Hepatitis C virus induce humoral and cellular responses in goats. Virol J. 2009; 6: 66[DOI][PubMed]
20.
Baldick CJ,
Wichroski MJ,
Pendri A,
Walsh AW,
Fang J,
Mazzucco CE,
et al.
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog. 2010; 6(9)[DOI][PubMed]
21.
Dorner M,
Horwitz JA,
Robbins JB,
Barry WT,
Feng Q,
Mu K,
et al.
A genetically humanized mouse model for hepatitis C virus infection. Nature. 2011; 474(7350): 208-11[DOI][PubMed]
22.
Sainz BJ,
Barretto N,
Martin DN,
Hiraga N,
Imamura M,
Hussain S,
et al.
Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat Med. 2012; 18(2): 281-5[DOI][PubMed]
23.
Mittapalli GK,
Zhao F,
Jackson A,
Gao H,
Lee H,
Chow S,
et al.
Discovery of ITX 4520: a highly potent orally bioavailable hepatitis C virus entry inhibitor. Bioorg Med Chem Lett. 2012; 22(15): 4955-61[DOI][PubMed]
24.
Zhu H,
Wong-Staal F,
Lee H,
Syder A,
McKelvy J,
Schooley RT,
et al.
Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. J Infect Dis. 2012; 205(4): 656-62[DOI][PubMed]
25.
Gededzha MP, Selabe SG, Kyaw T, Rakgole JN, Blackard JT, Mphahlele MJ. Introduction of new subtypes and variants of hepatitis C virus genotype 4 in South Africa. J Med Virol. 2012; 84(4): 601-7[DOI][PubMed]
26.
Gededzha MP, Selabe SG, Blackard JT, Kyaw T, Mphahlele MJ. Near full-length genome analysis of HCV genotype 5 strains from South Africa. Infect Genet Evol. 2014; 21: 118-23[DOI][PubMed]
27.
Koletzki D,
Dumont S,
Vermeiren H,
Peixe P,
Nina J,
Camacho RJ,
et al.
Full genome sequence of three isolates of hepatitis C virus subtype 4b from Portugal. Arch Virol. 2009; 154(1): 127-32
28.
Gasteiger E, Hoogland C, Gattiker A, Duvaud S, Wilkins MR, Appel RD. The Proteomics Protocols Handbook. 2005; : 571-607
29.
Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using recurrent neural network. Proteins. 2006; 65(1): 40-8[DOI][PubMed]
30.
Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol. 1999; 294(5): 1351-62[DOI][PubMed]
31.
Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatol. 2004; 39(1): 5-19
32.
Genovese D,
Dettori S,
Argentini C,
Villano U,
Chionne P,
Angelico M,
et al.
Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitis. J Clin Microbiol. 2005; 43(4): 1902-9
33.
Zhang P,
Zhong L,
Struble EB,
Watanabe H,
Kachko A,
Mihalik K,
et al.
Depletion of interfering antibodies in chronic hepatitis C patients and vaccinated chimpanzees reveals broad cross-genotype neutralizing activity. Proc Natl Acad Sci U S A. 2009; 106(18): 7537-41[DOI][PubMed]
34.
Tarr AW,
Urbanowicz RA,
Jayaraj D,
Brown RJ,
McKeating JA,
Irving WL,
et al.
Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. J Virol. 2012; 86(5): 2739-49[DOI][PubMed]
35.
Manzin A,
Solforosi L,
Petrelli E,
Macarri G,
Tosone G,
Piazza M,
et al.
Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol. 1998; 72(7): 6271-6[PubMed]
36.
Farci P,
Alter HJ,
Wong DC,
Miller RH,
Govindarajan S,
Engle R,
et al.
Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A. 1994; 91(16): 7792-6[PubMed]
37.
Ikram A, Anjum S, Tahir M. In Silico Identification and Conservation Analysis of B-cell and T-Cell Epitopes of Hepatitis C Virus 3a Genotype Enveloped Glycoprotein 2 From Pakistan: A Step Towards Heterologous Vaccine Design. Hepat Mon. 2014; 14(6)[DOI][PubMed]
38.
Yusim K,
Kesmir C,
Gaschen B,
Addo MM,
Altfeld M,
Brunak S,
et al.
Clustering patterns of cytotoxic T-lymphocyte epitopes in human immunodeficiency virus type 1 (HIV-1) proteins reveal imprints of immune evasion on HIV-1 global variation. J Virol. 2002; 76(17): 8757-68[PubMed]
39.
Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004; 54(2): 333-40[DOI][PubMed]
40.
Hrobowski YM, Garry RF, Michael SF. Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J. 2005; 2: 49[DOI][PubMed]
41.
Bai F,
Town T,
Pradhan D,
Cox J,
Ledizet M,
et al.
Antiviral peptides targeting the west nile virus envelope protein. J Virol. 2007; 81(4): 2047-55[DOI][PubMed]
42.
Liu R, Tewari M, Kong R, Zhang R, Ingravallo P, Ralston R. A peptide derived from hepatitis C virus E2 envelope protein inhibits a post-binding step in HCV entry. Antiviral Res. 2010; 86(2): 172-9[DOI][PubMed]
43.
Wang G. Post-translational Modifications of Natural Antimicrobial Peptides and Strategies for Peptide Engineering. Curr Biotechnol. 2012; 1(1): 72-9[PubMed]
44.
Beyene A, Basu A, Meyer K, Ray R. Hepatitis C virus envelope glycoproteins and potential for vaccine development. Vox Sang. 2002; 83 Suppl 1: 27-32[PubMed]